ARTICLE | Clinical News

DiaPep277: Phase III data

September 21, 2015 7:00 AM UTC

Horizon Pharma plc (NASDAQ:HZNP, Dublin, Ireland) said that Clal Biotechnology Industries Ltd. (Tel Aviv:CBI, Tel Aviv, Israel) provided the Tel Aviv Stock Exchange notice of data from the double-blind, international Phase III DIA-AID 2 trial in about 475 newly diagnosed Type I diabetics ages 20-45 with residual beta cell function showing that subcutaneous DiaPep277 missed the primary endpoint of improving beta cell function vs. placebo. Horizon said it does not have additional details, while Clal said it does not have the data. ...